Cargando…
Doxorubicin Is Key for the Cardiotoxicity of FAC (5-Fluorouracil + Adriamycin + Cyclophosphamide) Combination in Differentiated H9c2 Cells
Currently, a common therapeutic approach in cancer treatment encompasses a drug combination to attain an overall better efficacy. Unfortunately, it leads to a higher incidence of severe side effects, namely cardiotoxicity. This work aimed to assess the cytotoxicity of doxorubicin (DOX, also known as...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358964/ https://www.ncbi.nlm.nih.gov/pubmed/30634681 http://dx.doi.org/10.3390/biom9010021 |
_version_ | 1783392113094819840 |
---|---|
author | Pereira-Oliveira, Maria Reis-Mendes, Ana Carvalho, Félix Remião, Fernando Bastos, Maria de Lourdes Costa, Vera Marisa |
author_facet | Pereira-Oliveira, Maria Reis-Mendes, Ana Carvalho, Félix Remião, Fernando Bastos, Maria de Lourdes Costa, Vera Marisa |
author_sort | Pereira-Oliveira, Maria |
collection | PubMed |
description | Currently, a common therapeutic approach in cancer treatment encompasses a drug combination to attain an overall better efficacy. Unfortunately, it leads to a higher incidence of severe side effects, namely cardiotoxicity. This work aimed to assess the cytotoxicity of doxorubicin (DOX, also known as Adriamycin), 5-fluorouracil (5-FU), cyclophosphamide (CYA), and their combination (5-Fluorouracil + Adriamycin + Cyclophosphamide, FAC) in H9c2 cardiac cells, for a better understanding of the contribution of each drug to FAC-induced cardiotoxicity. Differentiated H9c2 cells were exposed to pharmacological relevant concentrations of DOX (0.13–5 μM), 5-FU (0.13–5 μM), CYA (0.13–5 μM) for 24 or 48 h. Cells were also exposed to FAC mixtures (0.2, 1 or 5 μM of each drug and 50 μM 5-FU + 1 μM DOX + 50 μM CYA). DOX was the most cytotoxic drug, followed by 5-FU and lastly CYA in both cytotoxicity assays (reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and neutral red (NR) uptake). Concerning the equimolar combination with 1 or 5 μM, FAC caused similar cytotoxicity to DOX alone. Even in the presence of higher concentrations of 5-FU and CYA (50 μM 5-FU + 1 μM DOX + 50 μM CYA), 1 μM DOX was still a determinant for the cardiotoxicity observed in the cytotoxicity assays, phase contrast morphological evaluation, and mitochondrial potential depolarization evaluation. To the best of our knowledge, this was the first in vitro work with this combination regimen, DOX being the most toxic drug and key to the toxicity of FAC. |
format | Online Article Text |
id | pubmed-6358964 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-63589642019-02-11 Doxorubicin Is Key for the Cardiotoxicity of FAC (5-Fluorouracil + Adriamycin + Cyclophosphamide) Combination in Differentiated H9c2 Cells Pereira-Oliveira, Maria Reis-Mendes, Ana Carvalho, Félix Remião, Fernando Bastos, Maria de Lourdes Costa, Vera Marisa Biomolecules Article Currently, a common therapeutic approach in cancer treatment encompasses a drug combination to attain an overall better efficacy. Unfortunately, it leads to a higher incidence of severe side effects, namely cardiotoxicity. This work aimed to assess the cytotoxicity of doxorubicin (DOX, also known as Adriamycin), 5-fluorouracil (5-FU), cyclophosphamide (CYA), and their combination (5-Fluorouracil + Adriamycin + Cyclophosphamide, FAC) in H9c2 cardiac cells, for a better understanding of the contribution of each drug to FAC-induced cardiotoxicity. Differentiated H9c2 cells were exposed to pharmacological relevant concentrations of DOX (0.13–5 μM), 5-FU (0.13–5 μM), CYA (0.13–5 μM) for 24 or 48 h. Cells were also exposed to FAC mixtures (0.2, 1 or 5 μM of each drug and 50 μM 5-FU + 1 μM DOX + 50 μM CYA). DOX was the most cytotoxic drug, followed by 5-FU and lastly CYA in both cytotoxicity assays (reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and neutral red (NR) uptake). Concerning the equimolar combination with 1 or 5 μM, FAC caused similar cytotoxicity to DOX alone. Even in the presence of higher concentrations of 5-FU and CYA (50 μM 5-FU + 1 μM DOX + 50 μM CYA), 1 μM DOX was still a determinant for the cardiotoxicity observed in the cytotoxicity assays, phase contrast morphological evaluation, and mitochondrial potential depolarization evaluation. To the best of our knowledge, this was the first in vitro work with this combination regimen, DOX being the most toxic drug and key to the toxicity of FAC. MDPI 2019-01-10 /pmc/articles/PMC6358964/ /pubmed/30634681 http://dx.doi.org/10.3390/biom9010021 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Pereira-Oliveira, Maria Reis-Mendes, Ana Carvalho, Félix Remião, Fernando Bastos, Maria de Lourdes Costa, Vera Marisa Doxorubicin Is Key for the Cardiotoxicity of FAC (5-Fluorouracil + Adriamycin + Cyclophosphamide) Combination in Differentiated H9c2 Cells |
title | Doxorubicin Is Key for the Cardiotoxicity of FAC (5-Fluorouracil + Adriamycin + Cyclophosphamide) Combination in Differentiated H9c2 Cells |
title_full | Doxorubicin Is Key for the Cardiotoxicity of FAC (5-Fluorouracil + Adriamycin + Cyclophosphamide) Combination in Differentiated H9c2 Cells |
title_fullStr | Doxorubicin Is Key for the Cardiotoxicity of FAC (5-Fluorouracil + Adriamycin + Cyclophosphamide) Combination in Differentiated H9c2 Cells |
title_full_unstemmed | Doxorubicin Is Key for the Cardiotoxicity of FAC (5-Fluorouracil + Adriamycin + Cyclophosphamide) Combination in Differentiated H9c2 Cells |
title_short | Doxorubicin Is Key for the Cardiotoxicity of FAC (5-Fluorouracil + Adriamycin + Cyclophosphamide) Combination in Differentiated H9c2 Cells |
title_sort | doxorubicin is key for the cardiotoxicity of fac (5-fluorouracil + adriamycin + cyclophosphamide) combination in differentiated h9c2 cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358964/ https://www.ncbi.nlm.nih.gov/pubmed/30634681 http://dx.doi.org/10.3390/biom9010021 |
work_keys_str_mv | AT pereiraoliveiramaria doxorubiciniskeyforthecardiotoxicityoffac5fluorouraciladriamycincyclophosphamidecombinationindifferentiatedh9c2cells AT reismendesana doxorubiciniskeyforthecardiotoxicityoffac5fluorouraciladriamycincyclophosphamidecombinationindifferentiatedh9c2cells AT carvalhofelix doxorubiciniskeyforthecardiotoxicityoffac5fluorouraciladriamycincyclophosphamidecombinationindifferentiatedh9c2cells AT remiaofernando doxorubiciniskeyforthecardiotoxicityoffac5fluorouraciladriamycincyclophosphamidecombinationindifferentiatedh9c2cells AT bastosmariadelourdes doxorubiciniskeyforthecardiotoxicityoffac5fluorouraciladriamycincyclophosphamidecombinationindifferentiatedh9c2cells AT costaveramarisa doxorubiciniskeyforthecardiotoxicityoffac5fluorouraciladriamycincyclophosphamidecombinationindifferentiatedh9c2cells |